Tilly H, Gomes da Silva M, Vitolo U, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v116-25. https://doi.org/10.1093/annonc/mdv304.

Article  PubMed  Google Scholar 

Merli F, Luminari S, Tucci A, et al. Simplified geriatric assessment in older patients with diffuse large B-Cell Lymphoma: the prospective elderly project of the fondazione Italiana Linfomi. J Clin Oncol. 2021;39(11):1214–22. https://doi.org/10.1200/jco.20.02465.

Article  CAS  PubMed  Google Scholar 

Sehn LH, Salles G. Diffuse large B-cell Lymphoma. N Engl J Med. 2021;384(9):842–58. https://doi.org/10.1056/NEJMra2027612.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chaganti S, Illidge T, Barrington S, et al. Guidelines for the management of diffuse large B-cell lymphoma. Br J Haematol. 2016;174(1):43–56. https://doi.org/10.1111/bjh.14136.

Article  PubMed  Google Scholar 

Goy A, Ramchandren R, Ghosh N, et al. Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL. Blood. 2019;134(13):1024–36. https://doi.org/10.1182/blood.2018891598.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hou K, Yu Z, Jia Y, et al. Efficacy and safety of ibrutinib in diffuse large B-cell lymphoma: a single-arm meta-analysis. Crit Rev Oncol/Hematol. 2020. https://doi.org/10.1016/j.critrevonc.2020.103010.

Article  PubMed  Google Scholar 

Rosenthal A, Younes A. High grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6: double hit and triple hit lymphomas and double expressing lymphoma. Blood Rev. 2017;31(2):37–42. https://doi.org/10.1016/j.blre.2016.09.004.

Article  CAS  PubMed  Google Scholar 

Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30(28):3452–9. https://doi.org/10.1200/jco.2011.41.0985.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hu S, Xu-Monette ZY, Tzankov A, et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from the International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013;121(20):4021–31. https://doi.org/10.1182/blood-2012-10-460063.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359(22):2313–23. https://doi.org/10.1056/nejmoa0802885.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Scott DW, Mottok A, Ennishi D, et al. Prognostic significance of diffuse large B-cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embedded tissue biopsies. J Clin Oncol. 2015;33(26):2848–56. https://doi.org/10.1200/JCO.2014.60.2383.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mareschal S, Lanic H, Ruminy P, et al. The proportion of activated B-cell like subtype among de novo diffuse large B-cell lymphoma increases with age. Haematologica. 2011;96(12):1888–90. https://doi.org/10.3324/haematol.2011.050617.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Klapper W, Kreuz M, Kohler CW, et al. Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma. Blood. 2012;119(8):1882–7. https://doi.org/10.1182/blood-2011-10-388470.

Article  CAS  PubMed  Google Scholar 

Reddy A, Zhang J, Davis NS, et al. Genetic and functional drivers of diffuse large B cell lymphoma. Cell. 2017;171(2):481–94. https://doi.org/10.1016/j.cell.2017.09.027.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25):1937–47. https://doi.org/10.1056/nejmoa012914.

Article  PubMed  Google Scholar 

Di M, Huntington SF, Olszewski AJ. Challenges and opportunities in the management of diffuse large B-cell lymphoma in older patients. Oncologist. 2021;26(2):120–32. https://doi.org/10.1002/onco.13610.

Article  PubMed  Google Scholar 

Récher C, Coiffier B, Haioun C, et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03–2B): an open-label randomised phase 3 trial. Lancet. 2021;378(9806):1858–67. https://doi.org/10.1016/s0140-6736(11)61040-4.

Article  Google Scholar 

Dunleavy K, Fanale MA, Abramson JS, et al. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. Lancet Haematol. 2018;5(12):e609–17. https://doi.org/10.1016/s2352-3026(18)30177-7.

Article  PubMed  PubMed Central  Google Scholar 

Bartlett NL, Wilson WH, Jung S-H, et al. Dose-adjusted EPOCH-R compared With R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III intergroup trial alliance/CALGB 50303. J Clin Oncol. 2019;37(21):1790–9. https://doi.org/10.1200/jco.18.01994.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Younes A, Thieblemont C, Morschhauser F, et al. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. Lancet Oncol. 2014;15(9):1019–26. https://doi.org/10.1016/s1470-2045(14)70311-0.

Article  CAS  PubMed  Google Scholar 

Younes A, Sehn LH, Johnson P, et al. Randomized phase III trial of Ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma. J Clin Oncol. 2019;37(15):1285–95. https://doi.org/10.1200/jco.18.02403.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wilson WH, Wright GW, Huang DW, et al. Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL. Cancer Cell. 2021;39(12):1643–53. https://doi.org/10.1016/j.ccell.2021.10.006.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dhillon S. Orelabrutinib: first approval. Drugs. 2021;81(4):503–7. https://doi.org/10.1007/s40265-021-01482-5.

Article  CAS  PubMed  Google Scholar 

Wang ML, Rule S, Martin P, et al. Targeting BTK with Ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507–16. https://doi.org/10.1056/nejmoa1306220.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Song Y, Song Y, Liu L, et al. Long-term safety and efficacy of Orelabrutinib monotherapy in Chinese patients with relapsed or refractory mantle cell lymphoma: a multicenter, open-label, phase II study. Blood. 2020;136:1–1. https://doi.org/10.1182/blood-2020-141781.

Article  Google Scholar 

O’Brien S, Furman RR, Coutre S, et al. Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. Blood. 2018;131(17):1910–9. https://doi.org/10.1182/blood-2017-10-810044.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu W, Zhou K, Wang T, et al. Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: multi-center, single-arm, open-label, phase 2 study. Am J Hematol. 2023. https://doi.org/10.1002/ajh.26826.

Article  PubMed  Google Scholar 

Wang M, Ke Q, Li Z, et al. 627MO Orelabrutinib plus RCHOP for previously untreated non-germinal center b cell-like (GCB) diffuse large b cell lymphoma (DLBCL) patients with extranodal disease. Ann Oncol. 2022;33:S830.

Article  Google Scholar 

Xu P-P, Liu T, Li Z, et al. Efficacy and safety of orelabrutinib in diffuse large B-cell lymphoma: a real-world analysis. J Clin Oncol. 2022;40(16_suppl):e19556.

Article  Google Scholar 

Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–90. https://doi.org/10.1182/blood-2016-01-643569.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wright GW, Huang DW, Phelan JD, et al. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell. 2020;37(4):551–68. https://doi.org/10.1016/j.ccell.2020.03.015.

Article  CAS  PubMed  PubMed Central  Google Scholar 

B-Cell Lymphoma. NCCN Guidelines Version 5.2022, https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf

Zhu J, Ma O. Union for China lymphoma investigators of Chinese society of clinical, Chinese society of clinical oncology (CSCO) diagnosis and treatment guidelines for malignant lymphoma 2021 (English version). Chin J Cancer Res. 2021;33(3):289–301. https://doi.org/10.21147/j.issn.1000-9604.2021.03.01.

Article  PubMed  PubMed Central